Coya Therapeutics, Inc. (NASDAQ:COYA) Given Consensus Rating of “Moderate Buy” by Brokerages

Coya Therapeutics, Inc. (NASDAQ:COYA) has been assigned an average rating of “Moderate Buy” from the six analysts that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $16.00.

COYA has been the subject of several research reports. Wall Street Zen upgraded Coya Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. BTIG Research raised their price target on Coya Therapeutics from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. D. Boral Capital reiterated a “buy” rating and set a $15.00 target price on shares of Coya Therapeutics in a research note on Wednesday, November 12th. Lake Street Capital reiterated a “buy” rating and issued a $17.00 price objective on shares of Coya Therapeutics in a research report on Wednesday, November 5th. Finally, HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of Coya Therapeutics in a research note on Monday, August 25th.

Coya Therapeutics Trading Up 5.3%

Shares of COYA stock opened at $6.16 on Wednesday. The company has a market capitalization of $128.87 million, a price-to-earnings ratio of -5.55 and a beta of 0.20. Coya Therapeutics has a 1-year low of $4.65 and a 1-year high of $8.29. The stock’s fifty day simple moving average is $6.07 and its 200-day simple moving average is $6.04.

Coya Therapeutics (NASDAQ:COYA) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.12). Coya Therapeutics had a negative return on equity of 55.76% and a negative net margin of 462.24%.The company had revenue of $3.56 million for the quarter, compared to analyst estimates of $3.70 million. On average, sell-side analysts predict that Coya Therapeutics will post -1.15 EPS for the current year.

Institutional Trading of Coya Therapeutics

Several hedge funds have recently modified their holdings of COYA. Prosperity Wealth Management Inc. raised its position in Coya Therapeutics by 16.4% in the 3rd quarter. Prosperity Wealth Management Inc. now owns 23,800 shares of the company’s stock valued at $136,000 after purchasing an additional 3,350 shares during the last quarter. Citadel Advisors LLC increased its holdings in Coya Therapeutics by 51.3% in the third quarter. Citadel Advisors LLC now owns 65,240 shares of the company’s stock valued at $372,000 after purchasing an additional 22,120 shares during the last quarter. Dauntless Investment Group LLC increased its stake in shares of Coya Therapeutics by 199.5% in the 3rd quarter. Dauntless Investment Group LLC now owns 153,021 shares of the company’s stock valued at $872,000 after acquiring an additional 101,932 shares during the last quarter. CM Management LLC raised its holdings in Coya Therapeutics by 50.0% in the third quarter. CM Management LLC now owns 300,000 shares of the company’s stock worth $1,710,000 after purchasing an additional 100,000 shares during the period. Finally, JPMorgan Chase & Co. acquired a new stake in Coya Therapeutics during the 3rd quarter worth $28,000. Institutional investors and hedge funds own 39.75% of the company’s stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.